ETR:BIO - Biotest Stock Price, News, & Analysis

+0.10 (+0.45 %)
(As of 07/18/2019 04:00 PM ET)
Today's Range
Now: €22.30
50-Day Range
MA: €22.96
52-Week Range
Now: €22.30
Volume1,363 shs
Average Volume1,927 shs
Market Capitalization$441.22 million
P/E Ratio5.37
Dividend Yield0.18%
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. Read More…

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$389.80 million
Cash Flow€3.21 per share
Book Value€16.46 per share



Market Cap$441.22 million
Next Earnings DateN/A

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Biotest (ETR:BIO) Frequently Asked Questions

What is Biotest's stock symbol?

Biotest trades on the ETR under the ticker symbol "BIO."

What price target have analysts set for BIO?

1 Wall Street analysts have issued twelve-month price targets for Biotest's stock. Their forecasts range from €24.10 to €24.10. On average, they expect Biotest's stock price to reach €24.10 in the next year. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for Biotest.

What is the consensus analysts' recommendation for Biotest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biotest in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biotest.

Has Biotest been receiving favorable news coverage?

Media coverage about BIO stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biotest earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Biotest.

Who are some of Biotest's key competitors?

What other stocks do shareholders of Biotest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest investors own include GRIFOLS S A/S (GRFS), ADMA Biologics (ADMA) and CSL (CSL).

Who are Biotest's key executives?

Biotest's management team includes the folowing people:
  • Dr. Bernhard R. M. Ehmer, Chairman of Management & CEO (Age 64)
  • Dr. Michael Ramroth, CFO, Head of Fin.s & Central Services and Member of the Board of Management
  • Dr. Georg Floß, COO & Member of the Board of Management
  • Dr. Monika Buttkereit, Head of Investor Relations
  • Dr. Christina Erb, Head of Corp. HR

What is Biotest's stock price today?

One share of BIO stock can currently be purchased for approximately €22.30.

How big of a company is Biotest?

Biotest has a market capitalization of $441.22 million and generates $389.80 million in revenue each year. Biotest employs 1,663 workers across the globe.View Additional Information About Biotest.

What is Biotest's official website?

The official website for Biotest is

How can I contact Biotest?

Biotest's mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company can be reached via phone at +49-6103-8010.

MarketBeat Community Rating for Biotest (ETR BIO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Biotest and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel